Record Details

Shatavarin-IV saponin adjuvant elicits IgG and IgG2b responses against Staphylococcus aureus bacterin in a murine model

KRISHI: Publication and Data Inventory Repository

View Archive Info
 
 
Field Value
 
Title Shatavarin-IV saponin adjuvant elicits IgG and IgG2b responses against Staphylococcus aureus bacterin in a murine model
Not Available
 
Creator Arivukarasu Palanisamy, Rinku Sharma, Prithvi Pal Singh, Upendra Sharma, Rajendra Damu Patil, Gorakh Mal, Birbal Singh
 
Subject Shatavarin-IV (S-IV) isolation and characterization, Asparagus adscendens fruit, Inactivated S. aureus (Bacterin), Shatavarin-IV adjuvant, Immune response
 
Description Not Available
Asparagus adscendens Roxb. also known as “safed musli” or “shatavari” is a medicinal plant
commonly found in South Asian countries. Shatavari is effective for the treatment of gastric ul cers, renal stones, bronchitis, diabetes, diabetic neuropathy, irritable bowel syndrome, alcohol
withdrawal and has reported immunostimulatory effects. In this study, the adjuvant potential of
Shatavarin-IV saponin against Staphylococcus aureus bacterin in mice was investigated.
Shatavarin-IV was evaluated for its toxicity and immunomodulatory potential against S. aureus
bacterin in mice. Cellular and humoral immune responses were assessed. Shatavarin-IV was
isolated from the fruit extract of Asparagus adscendens. The confirmation of the isolated molecule
as Shatavarin-IV was done via TLC-based comparison with the standard molecule. Further, the
structure was confirmed by using extensive spectroscopic analyses and comparing the observed
data with literature reports. It was found safe up to the dose of 0.1 mg in the mice model.
Shatavarin-IV adjuvant elicited IgG and IgG2b responses at the dose of 40 μg against S. aureus
bacterin. However, the cell-mediated immune response was lesser as compared with the com mercial Quil-A saponin . We demonstrated that Shatavarin-IV saponin adjuvant produced an
optimum humoral immune response against S. aureus bacterin. These results highlight the po tential of Shatavarin-IV as an adjuvant in a combination adjuvant in vaccine formulations for
induction of potent immune response.
Not Available
 
Date 2023-05-30T04:36:09Z
2023-05-30T04:36:09Z
2023-01-01
 
Type Research Paper
 
Identifier Not Available
Not Available
http://krishi.icar.gov.in/jspui/handle/123456789/77885
 
Language English
 
Relation Not Available;
 
Publisher Not Available